Experience
Heart Failure
Cardiovascular studies across the ejection-fraction spectrum.
Explore heart failure trials
GCSA-Certified Cardiovascular Trial Site. Cardiac PET studies supported through our affiliated imaging partner.
Where Tomorrow's Cardiovascular Therapies Are Tested -- and Today's Patients Get First Access
Six active cardiovascular studies at our operating North Miami Beach clinical trial site and heart practice, with our operating Kendall cardiovascular surgery center supporting procedural work. Cardiac PET studies are supported through our affiliated imaging partner. 19 pharma and device sponsors including Alnylam, Pfizer, and Pharmacosmos. GCSA-certified. Led by a senior principal investigator with a structural-heart (TAVR) research background. Sponsors get audit-ready data on schedule. Patients get tomorrow's standard of care, today, at no cost.
Led by Dr. William O'Neill — senior principal investigator and interventional cardiologist with a structural-heart (TAVR) research background
GCSA
GCSA-certified (Feb 2025)
15+
Years of Experience
Therapeutic Areas
Cardiovascular indications we support today
Our Miami site supports heart failure, hypertension, peripheral artery disease, atrial fibrillation through EP capability, and structural heart studies.
Experience
Hypertension
Treatment-resistant hypertension studies at our Miami site.
Explore hypertension trialsExperience
Peripheral Artery Disease
Peripheral vascular and atherectomy research capabilities.
Explore PAD trialsEP capability
Atrial Fibrillation
Cardiac electrophysiology capability for atrial fibrillation protocols.
Explore EP capabilityCapability
Structural Heart
Structural heart research led by experienced cardiovascular investigators.
Explore structural heartCardiovascular research is our core. Immunology, oncology, and neurology are expansion areas through imaging-enabled subcontracted scopes, with Amavita as prime contractor and our affiliated imaging partner performing imaging. We do not currently run oncology, neurology, or immunology trials at our site. We do not offer gastroenterology or rheumatology studies.
Leadership
Cardiovascular Research Leadership
Dr. William W. O'Neill is a senior principal investigator and interventional cardiologist with a structural-heart (TAVR) research background at Amavita Research.
Our leadership team combines interventional expertise with proven clinical research execution.
Dr. William W. O'Neill, MD, FACC
Chief Medical Officer & Senior Principal Investigator
Senior principal investigator and interventional cardiologist with a structural-heart (TAVR) research background. Medical Director, Center for Structural Heart Disease, Henry Ford Hospital · Chief Medical Advisor, CardioElite™. He served as National Principal Investigator (chair) of the PROTECT II trial; Steering Committee member for PROTECT IV; Principal Investigator at Henry Ford for the PARTNER trial.
Dr. Pedro Martinez-Clark, MD, FACC
Founder and Lead Investigator
Harvard-trained interventional cardiologist with 15+ years of experience and more than 25 clinical research trials, including pivotal work helping develop the Trans-Caval TAVR approach and serving as Worldwide PI on the Percutaneous Mitral Valve Annuloplasty trial. Founder and CEO of amavita Heart and Vascular Health® — independent Miami cardiovascular practice; 16,000+ patients seen in the last 3 years.
Julio G. Martinez-Clark
Chief Executive Officer (CEO)
Drives growth strategy, sponsor relationships, and cross-border trial operations at Amavita Research. CEO of bioaccess® with 20+ years scaling clinical research operations across the Americas. Former Ambassador of IAOCR / GCSA Americas.
Our Group
One Miami group, four business lines
Amavita Research Services — this site — is the cardiovascular trial-site business of a Miami group of four companies. Each company operates independently under its own name and contracts on its own; together they cover a program from first-in-human (FIH) trials to US expansion cohorts.
You're here
Amavita Research Services
Miami cardiovascular trial site — the cardiac Phase 1 unit: an 8-bed telemetry unit inside a cardiovascular ambulatory surgery center (ASC), led by a cardiologist principal investigator.
Why it helps you: run cardiac early-phase and FIH work where the cardiology practice and cath-lab access live.
bioaccess®
Our sister contract research organization (CRO): first-in-human (FIH) trials across Latin America, Canada, and the United States, with US-anchored regulatory strategy.
Why it helps you: start your program in Latin America with bioaccess, then bring expansion cohorts to our Miami site — one team, one contact.
Amavita Sciences™
Our sister company bridging Asia–Latin America regulatory document translation.
Why it helps you: trial documents and dossiers translated for Latin American regulators — no language gap between submission and approval.
Amavita Heart and Vascular Health®
Our cardiology clinical practice — the patient-care arm of the group and the referral base behind the research site.
Why it helps you: Trial participants recruited from an active cardiology practice — real patients, not database cold-calls.
Taking a molecule from first-in-human to US expansion?
Our sister organization bioaccess® runs FIH programs across Latin America — 50+ delivered since 2010. Pair it with our GCSA-certified Miami site for your expansion cohorts. One team, one contact.
Affiliated ASCOur Surgical Center Advantage
A Dedicated Cardiovascular ASC in Miami
A licensed, Medicare-certified, AAAHC-accredited cardiovascular ASC in Kendall, Miami, affiliated with Amavita Research.
Amavita Research patients and sponsor trials have direct access to Advanced Cardiovascular of Miami — an affiliated, licensed, Medicare-certified, AAAHC-accredited cardiovascular ambulatory surgery center in Kendall, Miami, with cath lab access for same-day procedures.
3D ImagingCardiac Mapping SystemCatheterization LabsMinimally Invasive Interventional SuitesOne-Stop Diagnosis-to-Intervention Workflow
9408 SW 87th Ave, Suite 303, Miami, FL 33176
Active Studies
Current Breakthrough Studies
Investigating tomorrow's standards of care across cardiology, hypertension, and vascular medicine.
Phase 2Heart Failure● Enrolling
Pfizer BRANCH-HF (C4921003) — PF-07328948 in HFpEF
Heart Failure with Preserved Ejection Fraction (HFpEF)
C4921003
Phase 2 study of PF-07328948, an oral branched-chain ketoacid dehydrogenase (BCKD) kinase inhibitor, in adults with heart failure. The trial evaluates the metabolic pathway that branched-chain amino acid catabolism plays in cardiac function in HFpEF.
Eligibility & detailsPhase 3Hypertension● Enrolling
ZENITH — Zilebesiran in Uncontrolled Hypertension
Hypertension with Cardiovascular Risk
ALN-AGT01-008
Phase 3 study of zilebesiran in patients with hypertension not adequately controlled and with either established cardiovascular disease or high risk for cardiovascular disease. Zilebesiran is a subcutaneous RNAi therapeutic targeting hepatic angiotensinogen.
Eligibility & detailsPhase 3Heart Failure● Enrolling
ICONIC-HF — Ferric Derisomaltose in Iron-Deficiency Heart Failure
Iron-Deficiency Chronic Heart Failure
P-Monofer-CHF-02
Phase 3 trial of ferric derisomaltose (intravenous iron) versus no intravenous iron in iron-deficient subjects with symptomatic chronic heart failure. ICONIC-HF measures the impact of IV iron supplementation on HF outcomes.
Eligibility & detailsPivotalVascular● Enrolling
GREAT — Golazo® Peripheral Atherectomy System
Peripheral Artery Disease
AVA-CL-5000
The GREAT Trial evaluates the Golazo® Peripheral Atherectomy System for safe and effective atherectomy in patients with peripheral artery disease. Phase: device IDE study.
Eligibility & detailsPhase 1/2Heart Failure● Enrolling
VASA — Heart Failure with Preserved Ejection Fraction
Heart Failure with Preserved Ejection Fraction (HFpEF)
VS-041-102
A safety, tolerability, and biomarker trial of VS-041 in participants with Heart Failure with Preserved Ejection Fraction. Amavita Research Services is an enrolling site under Medpace clinical trial agreement, with Dr. Pedro Martinez-Clark as Principal Investigator.
Eligibility & detailsRegistryHeart Failure● Start-up
OPEN HF Registry — Impulse Dynamics
Heart failure — cardiac contractility modulation (CCM)
OPEN HF
Cardiac contractility modulation (CCM) heart-failure registry. Amavita Research Services, LLC is a start-up site under a CTA executed 19 August 2026.
Eligibility & detailsTrusted by leading sponsors
- Pfizer
- Alnylam Pharmaceuticals
- Pharmacosmos
- Avantec / Nipro
- Vasa Therapeutics
- Impulse Dynamics
- Novo Nordisk
- Salubris / JK07 Bio
- AnaCardio
- Janssen
- Cardurion Pharmaceuticals
- River 2 Renal
- Cordio Medical
- GE Healthcare
- AngioDynamics
- Revive Therapeutics
- Vifor / Relypsa
- ImpediMed
- Boehringer Ingelheim
Pharmaceutical, biotech, and device partners across active and completed trials
For Patients
Access tomorrow's treatments today
- Compassionate, board-certified investigators
- Compensation for time and travel
- No-cost study-related care and lab work
- Trilingual coordinators (EN / ES / HT)
For Sponsors
A trusted partner for high-quality data
- senior principal investigator and interventional cardiologist with a structural-heart (TAVR) research background
- Proven enrollment in cardiometabolic trials
- Diverse Miami patient population
- Modern infrastructure and EDC fluency
- Heart failure, hypertension, and peripheral artery disease studies
- Atrial fibrillation EP capability and structural heart research
- Cardiac PET studies supported through our affiliated imaging partner
- AI-powered study sourcing & patient feasibility (Trial Radar)
Cardiovascular capability pages: Oncology expansion · Neurology expansion · Cardiac PET support · Trial-site capabilities · Sponsor support · Trial Radar — how we find your study
FAQ
Frequently Asked Questions
Quick answers about clinical trials, leadership, location, and what participation involves at Amavita Research.
Locations
Two Miami-Dade locations, operating now
Operating now
North Miami Beach
100 NW 170 St, Suite 305North Miami Beach, FL 33169
Legal address of Amavita Research, clinical trial site and heart practice.
Operating now
Kendall
9408 SW 87th Ave, Suite 303Miami, FL 33176
Cardiovascular surgery center.
Insights
Latest from our blog
Plain-language education on clinical trials, conditions, and procedures — written for patients and partners.
For Patients
What to Expect as a Patient in a Cardiovascular Clinical Trial
From the first phone call through the final follow-up visit, here is a step-by-step look at what participating in a cardiovascular clinical trial actually involves.
Read moreClinical Research Basics
Clinical Trial Phases Explained: Phase 1 vs Phase 2 vs Phase 3
Drug clinical trials are organized into phases. Each one answers different safety and effectiveness questions. Here is what each phase is for, in plain language.
Read moreClinical Research Basics
How First-in-Human Cardiovascular Trials Are Conducted Safely
First-in-human (FIH) trials are the first time a new therapy is studied in people. Here is how protocols, oversight, and site experience combine to keep participants safe.
Read moreReady to take the next step?
Whether you are a patient seeking new treatment options or a sponsor planning your next study, our team is ready to help.